Biolog

Biolog provides cell-based phenotyping technologies and assays that enable researchers to characterize microbial and mammalian cells through their metabolic and biochemical activity profiles. The company's phenotype microarray technology allows high-throughput screening of cellular responses to thousands of chemical compounds and environmental conditions simultaneously, generating comprehensive phenotypic fingerprints that reveal metabolic pathways, drug resistance mechanisms, and cellular function. Biolog's assays are used across pharmaceutical development, agricultural biotechnology, environmental microbiology, and academic research, supporting applications including antimicrobial susceptibility testing, cell line characterization, microbial identification, and functional genomics. The company's platform differentiates itself through its ability to measure live cell responses in real-time across hundreds of conditions in a single experiment, providing functional data that complements genomic and proteomic analysis. Founded in 1984 and headquartered in Hayward, California, Biolog has raised approximately $33.6 million in a Series A round backed by Broadoak Capital Partners, RCT, Redfund Capital, and HHS.